STOCK TITAN
The best stock market news and trading tools all in one place—your must-have platform for investing success.
A must-have platform for stock market information, offering the best tools and updates to supercharge your trading.
Your trusted source for the best stock market news, trading tools, and expert advice. Everything traders need, in one place.

Personalis to Participate at the Oppenheimer MedTech, Tools & Diagnostics Summit

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Personalis, Inc. (Nasdaq: PSNL), a leader in cancer genomics, will participate in the Oppenheimer MedTech, Tools & Diagnostics Summit on May 26, 2021. This event will showcase the company’s advancements in population sequencing and the ImmunoID NeXT Platform, which offers comprehensive molecular data on cancer and immune response. The presentation will be available for 90 days on Personalis’ website, emphasizing their role as the sole sequencing provider for the U.S. Department of Veterans Affairs Million Veterans Program.

Positive
  • None.
Negative
  • None.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the Oppenheimer MedTech, Tools & Diagnostics Summit on Wednesday, May 26, 2021.

Interested parties may access the pre-recorded and archived webcast of the presentation for 90 days following the conference through the “Events” section of Personalis’ website at http://investors.personalis.com.

About Personalis, Inc.

Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing programs globally and is currently the sole sequencing provider to the U.S. Department of Veterans Affairs Million Veterans Program. In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue or blood sample. The Personalis® Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited.

FAQ

When will Personalis, Inc. present at the Oppenheimer MedTech Summit?

Personalis, Inc. will present at the Oppenheimer MedTech, Tools & Diagnostics Summit on May 26, 2021.

Where can I access the Personalis presentation from the Oppenheimer Summit?

The presentation will be available for 90 days on Personalis' website in the 'Events' section.

What is the focus of Personalis, Inc. in cancer genomics?

Personalis focuses on providing comprehensive molecular data about cancer and immune responses, using their ImmunoID NeXT Platform.

Who is the sole sequencing provider for the U.S. Department of Veterans Affairs Million Veterans Program?

Personalis, Inc. is the sole sequencing provider for the U.S. Department of Veterans Affairs Million Veterans Program.

Personalis, Inc.

NASDAQ:PSNL

PSNL Rankings

PSNL Latest News

PSNL Stock Data

277.65M
54.05M
19.3%
53.15%
4.58%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
FREMONT